Article Details
Retrieved on: 2025-07-05 17:47:55
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
A potential buyer like Pfizer or AbbVie could pay $3–5 billion upfront for this asset, mirroring Roche's Televant deal. 2. Immunovant (Batoclimab).
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here